Swati Gupta currently serves as Lecturer at the Department of Pharmaceutics, School of Pharmacy, Health Science Campus, Kochi. 






Publication Type: Journal Article
Year of Publication Publication Type Title
2016 Journal Article Da Subramanian and Swati P. Gupta, “Pharmacokinetic study of amaranth extract in healthy humans: A randomized trial”, Nutrition, vol. 32, pp. 748-753, 2016.[Abstract]

Objective: Nitric oxide (NO) is one of the most important signaling molecules produced within the body. Continuous generation of NO is essential for the integrity of the cardiovascular system. The aim of this study was to assess whether oral intake of a nitrate (NO3 -)-rich dietary supplement (amaranth extract) is able to increase NO3 - and nitrite (NO2 -) levels in blood plasma and saliva of healthy adults. Methods: In the present study, bioavailability and pharmacokinetics of NO3 - and NO2 - from amaranth extract (2 g as single dose) was studied in 16 healthy individuals and compared with placebo in a crossover design. The NO3 - and NO2 - levels in plasma as well as saliva were measured up to 24 h. Results: After administration of amaranth extract, the NO3 - levels in plasma as well as saliva were found to be significantly (P < 0.001) higher than in the placebo group. The NO2 - level in plasma was slightly higher (P < 0.05) in the amaranth group (test group) compared with that in the placebo group, whereas the saliva NO2 - level was significantly high (P < 0.001) in the amaranth extract-treated group than the placebo group. Conclusions: These results clearly indicate that a single oral dose of amaranth extract is able to increase the NO3 - and NO2 - levels in the body for at least 8 h. The increase in NO3 - and NO2 - levels can help to improve the overall performance of people involved in vigorous physical activities or sports. © 2016 Elsevier Inc.

More »»
2015 Journal Article Anilkumar B. Pillai, Nair, J. Va, Gupta, N. Kb, and Swati P. Gupta, “Microemulsion-loaded hydrogel formulation of butenafine hydrochloride for improved topical delivery”, Archives of Dermatological Research, 2015.[Abstract]

Topical microemulsion systems for the antifungal drug, butenafine hydrochloride (BTF) were designed and developed to overcome the problems associated with the cutaneous delivery due to poor water solubility. The solubility of BTF in oils, surfactants and co-surfactants was evaluated to screen the components of the microemulsion. Isopropyl palmitate was used as the oil phase, aerosol OT as the surfactant and sorbitan monooleate as co-surfactant. The pseudoternary diagrams were constructed to identify the area of microemulsion existence and optimum systems were designed. The systems were assessed for drug-loading efficiency and characterized for pH, robustness to dilution, globule size, drug content and stability. Viscosity analysis, spreadability, drug content assay, ex vivo skin permeation study and antifungal activity assay were performed for the optimized microemulsion-loaded hydrogel. The optimized BTF microemulsion had a small and uniform globule size. The incorporation of microemulsion system into Carbopol 940 gel was found to be better as compared to sodium alginate or hydroxyl propyl methyl cellulose (HPMC K4 M) gel. The developed gel has shown better ex vivo skin permeation and antifungal activity when compared to marketed BTF cream. Thus, the results provide a basis for the successful delivery of BTF from microemulsion-loaded hydrogel formulation, which resulted in improved penetration of drug and antifungal activity in comparison with commercial formulation of BTF. © 2015 Springer-Verlag Berlin Heidelberg

More »»
2014 Journal Article Swati P. Gupta and Mohan, C. Gb, “Dual binding site and selective acetylcholinesterase inhibitors derived from integrated pharmacophore models and sequential virtual screening”, BioMed Research International, vol. 2014, 2014.[Abstract]

In this study, we have employed in silico methodology combining double pharmacophore based screening, molecular docking, and ADME/T filtering to identify dual binding site acetylcholinesterase inhibitors that can preferentially inhibit acetylcholinesterase and simultaneously inhibit the butyrylcholinesterase also but in the lesser extent than acetylcholinesterase. 3D-pharmacophore models of AChE and BuChE enzyme inhibitors have been developed from xanthostigmine derivatives through HypoGen and validated using test set, Fischer's randomization technique. The best acetylcholinesterase and butyrylcholinesterase inhibitors pharmacophore hypotheses Hypo1-A and Hypo1-B, with high correlation coefficient of 0.96 and 0.94, respectively, were used as 3D query for screening the Zinc database. The screened hits were then subjected to the ADME/T and molecular docking study to prioritise the compounds. Finally, 18 compounds were identified as potential leads against AChE enzyme, showing good predicted activities and promising ADME/T properties. © 2014 Shikhar Gupta and C. Gopi Mohan.

More »»
Faculty Details



Faculty Research Interest:

Faculty Email: